SEC Form SC 13G/A filed by Cutera Inc. (Amendment)
$CUTR
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/22/2024 | Underperform → Mkt Perform | William Blair | |
| 7/27/2023 | $14.00 → $18.00 | Underweight → Neutral | Piper Sandler |
| 5/11/2023 | Outperform → Mkt Perform | William Blair | |
| 5/10/2023 | $14.00 | Underweight | Piper Sandler |
| 3/30/2023 | Buy → Hold | Maxim Group | |
| 1/31/2023 | Mkt Perform | William Blair | |
| 1/11/2023 | $85.00 → $33.00 | Overweight → Neutral | Cantor Fitzgerald |
| 12/28/2022 | $78.00 → $68.00 | Overweight | Stephens |
4 - CUTERA INC (0001162461) (Issuer)
4 - CUTERA INC (0001162461) (Issuer)
3 - CUTERA INC (0001162461) (Issuer)
EFFECT - CUTERA INC (0001162461) (Filer)
POS AM - CUTERA INC (0001162461) (Filer)
25 - CUTERA INC (0001162461) (Filer)
Emerges from Chapter 11 as a stronger company, well positioned for long-term growth Continuing to provide best-in-class aesthetic and dermatology solutions to customers CUTERA, INC., ("Cutera" or "the Company"), a leading provider of aesthetic and dermatology solutions, today announced that the Company has successfully completed its financial restructuring process and emerged from Chapter 11. Cutera emerges with a significantly stronger balance sheet, well positioned to drive innovation and growth. Through this process, Cutera has reduced its debt by nearly $400 million, or over 90%, and raised $65 million in new money financing from its existing lenders. "Today marks a significant mile
Cutera, Inc. ("Cutera" or the "Company") (NASDAQ:CUTR) today announced that it has formally notified The Nasdaq Stock Market LLC ("Nasdaq") of its intent to voluntarily delist its common stock from the Nasdaq Global Select Market. Cutera expects to file a Form 25 with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 20, 2025. The Company expects the delisting of the common stock to be effective on or about March 30, 2025. Following such delisting, the Company intends to file a Form 15 with the SEC to indefinitely suspend the Company's reporting obligations under the Securities Exchange Act of 1934, as amended. The s
Enters into agreement to reduce debt by nearly $400 million and raise $65 million of new money from existing lenders Implementing pre-packaged financial restructuring plan with strong support of lenders, expected to emerge expeditiously within 60 days Continues to operate as usual and provide best-in-class aesthetic and dermatology solutions to customers CUTERA, INC., ("Cutera" or "the Company"), a leading provider of aesthetic and dermatology solutions, today announced that it is initiating a restructuring transaction with the support of a group of existing lenders, representing approximately 74% of the Company's notes, to strengthen its balance sheet and position Cutera for long-term s
William Blair upgraded Cutera from Underperform to Mkt Perform
Piper Sandler upgraded Cutera from Underweight to Neutral and set a new price target of $18.00 from $14.00 previously
William Blair downgraded Cutera from Outperform to Mkt Perform
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2024. Consolidated revenue for the third quarter of 2024 of $32.5 million Cash, cash equivalents, and restricted cash of $59.0 million AviClear growth of 16% vs prior year period driven by international capital system sales Global core capital growth of 7% on a sequential quarterly basis Full-year guidance maintained for both revenue and year-end cash balance "Our third quarter reflects consistent execution against our strategic priorities, with core capital sales improving on a sequential basis, AviClear continuing to
Cutera, Inc. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call at the following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remai
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024. Consolidated revenue for the second quarter of 2024 of $34.4 million Cash, cash equivalents, and restricted cash of $84.3 million AviClear growth of 41% vs prior year period driven by international capital system sales Service growth of 7% vs prior year period, highlighting improvements in field service and overall customer support Completion of the Q4 2023 corporate restructuring program, and announcement of additional cost reduction initiatives, allowing for both improved cost structure and better organization al
SC 13G/A - CUTERA INC (0001162461) (Subject)
SC 13G/A - CUTERA INC (0001162461) (Subject)
SC 13D/A - CUTERA INC (0001162461) (Subject)
Experienced Healthcare Executive Brings Extensive Financial and Operational Expertise to Cutera Board of Directors CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that Jeryl "Jeri" Hilleman will join its Board of Directors, effective July 12, 2024. Ms. Hilleman brings over 30 years of experience in the healthcare industry, with a proven track record in financial leadership, strategic planning, operational excellence, and corporate governance. Her extensive background in life sciences and medical technology, both as a public company CFO and as a corporate director, will be invaluable to Cutera as it continues to innovate, drive towar
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step
Hauser Brings Over 20 Years of Aesthetics Industry Experience in Markets Across the Globe Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Brent Hauser as President, International, effective October 2, 2023. Mr. Hauser will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for commercial performance in existing international markets, expansion into new geographies, and the international launch of AviClear, the company's pioneering energy-based device for the treatment of mild to severe acne, in 2024. Mr. Hauser brings over 20 years of aest